ESMO 2017 | Should all platinum sensitive patients recieve PARP inhibitors?

Domenica Lorusso

Domenica Lorusso, MD, PhD, from the Fondazione IRCCS Instituto Nazionale Dei Tumori, Milan, Italy, discusses the ARIEL3 study (NCT01968213) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. This is a randomised Phase III trial comparing PARP inhibitor rucaparib to placebo as maintenance treatment in platinum sensitive recurrent ovarian cancer. The results of this trial were particularly positive in patients with BRCA mutations, as well as with no HRD. Dr Lorusso states that these results suggest that platinum sensitive patients should receive PARP inhibitors.

Share this video